Open-Label Extension of Other SZ1839 (Iressa) Trials
Launched by ASTRAZENECA · Mar 13, 2008
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Received treatment in a previous Iressa clinical trial
- • Provided Informed Consent to participate in the trial
- • 30 days or less since completing the previous Iressa trial.
- Exclusion Criteria:
- • Radiotherapy completed more than 14 days before starting treatment in this trial
- • Incomplete healing from prior surgery
- • Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials